Use the hyperlinks, where available to access additional clinical trial information.
DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Australasian Lung Cancer Trials Group (ALTG)
PrECOG, LLC & AstraZeneca
Other Non-Commercial Sponsor
University of Sydney
Two thirds of eligible patients will be randomly assigned to receive durvalumab in addition to standard chemotherapy containing pemetrexed and cisplatin. One third of eligible patients will receive chemotherapy alone, followed by observation.